The intracellular concentration of cholesterol is a vital constant influenced by the uptake, metabolism and excretion of cholesterol. The synthesis and expression of the PCSK9-LDLR duo is one of the most important mechanisms to regulate this constant; in a physiological state, the yin-yang balance between PCSK9 and LDLR regulates the entry of cholesterol into the cell to keep the intracellular cholesterol concentration stable.
The mapping of the human gene encoding the serine protease PCSK9, located at 1p32-3, has allowed the identification of mutations with "gain" and "loss" of protease functions. Gain of function mutations causes decreased LDLR resulting in increased LDL-C and increased incidence of cardiovascular events. Loss of function mutations have opposite effect, increased LDLR, decreased LDL-C and decreased incidence of cardiovascular events.
The identification of human mutations with PCSK9 “loss” of function demostrated the benefit of decreased PCSK9 and opened the door to developing new anti-PCSK9 therapies. The goal of this research area is to reduce the incidence of cardiovascular events beyond statins; the strategy is to mimic the state of PCSK9 “loss” of function by tactics as oligonucleotide therapies targeting PCSK9 mRNA and/or biological therapies with human monoclonal antibodies targeting PCSK9.
This chapter reviews, the characteristics of the PCSK9, the physiological significance of the PCSK9-LDLR duo, and the therapeutic implications of the human genetic models of PCSK9 “loss” of function. The phase I-II clinical trial data of two promising monoclonal antibodies to PCSK9, Alirocumab formerly SAR236553/REGN727and AMG145 will be presented.
Keywords: Alirocumab, ALN-PCS, AMG145, cholesterol, familiar-hypercholesterolemia, hypocholesterolemia, LDLR, mAbPCSK9, non-familiar-hypercholesterolemia, PCSK9, PCSK9- gain-of-function, PCSK9-mutations, PCSK9-loss-of-function, serine-proteases, subtilases.
The Heme Oxygenase System Selectively Modulates Proteins Implicated in Metabolism, Oxidative Stress and Inflammation in Spontaneously Hypertensive Rats
Current Pharmaceutical Design Omega-3 Fatty Acids and HDL. How Do They Work in the Prevention of Cardiovascular Disease?
Current Vascular Pharmacology Patents and Heart Valve Surgery - II: Tissue Valves
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Angiotensin II Type 1 Receptor Binding Molecule ATRAP as a Possible Modulator of Renal Sodium Handling and Blood Pressure in Pathophysiology
Current Medicinal Chemistry Lipid Peroxidation End-Products as Modulators of Catabolic and Inflammatory Responses in Arthritis: A Review
Current Rheumatology Reviews A Pilot Study to Assess Adenosine 5’-triphosphate Metabolism in Red Blood Cells as a Drug Target for Potential Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets Impacts of Nanoparticles on Cardiovascular Diseases: Modulating Metabolism and Function of Endothelial Cells
Current Drug Metabolism Astrocyte Influences on Ischemic Neuronal Death
Current Molecular Medicine Role of Bisphosphonates in Vascular calcification and Bone Metabolism: A Clinical Summary
Current Cardiology Reviews β-Adrenomimetic Actions in the Hypotension and Vasodilatation Induced by a Chromatographic Active Fraction from Bidens pilosa L. (Asteraceae) in Mammals
Current Bioactive Compounds Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews Nucleic Acid Drugs for Preventing Restenosis after Coronary Revascularization
Current Topics in Medicinal Chemistry Immunoglobulin Therapy, Myocardial Diseases and Atherosclerosis:Recent Experimental and Clinical Studies
Current Cardiology Reviews Further Vitamin D Analogs
Current Vascular Pharmacology Dl-3-n-Butylphthalide (NBP): A Promising Therapeutic Agent for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Molecular Basis of Young Ischemic Stroke
Current Medicinal Chemistry Soluble RAGE-Modulating Drugs: State-of-the-Art and Future Perspectives for Targeting Vascular Inflammation
Current Vascular Pharmacology Meet Our Editorial Board Member:
Current Vascular Pharmacology The Roles of Cytochrome P450 in Ischemic Heart Disease
Current Drug Metabolism Safety and Efficacy of Tirofiban as an Adjunctive Therapy for Patients with St-Elevation Myocardial Infarction: A Comparison Versus Placebo and Abciximab
Cardiovascular & Hematological Agents in Medicinal Chemistry